ZNHIT3 (Gene)

Synonyms:ENTREZ:9326, HGNC:12309, Hit1, MIM:604500, NM_001033577, NM_001281432, NM_001281433, NM_001281434, NM_004773, NP_001268361, NP_001268362, NP_001268363, NP_004764, NR_104009, NR_104010, NR_104011, PEHO, TRIP3, ZNHIT3, zinc finger HIT-type containing 3
Id:ENSG00000278574
Description:zinc finger HIT-type containing 3 [Source:HGNC Symbol;Acc:HGNC:12309]
Predicted to enable thyroid hormone receptor binding activity. Predicted to be involved in box C/D snoRNP assembly; maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA); and snoRNA localization. Located in cytoplasm and nucleus. Implicated in PEHO syndrome. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ZNHIT3's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ZNHIT3.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ZNHIT3.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ZNHIT3.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ZNHIT3.

Results found

Linked to

 

Label

Description

 

Phenotype

Loss of visual acuity (implying that vision was better at a certain time point in life). Otherwise t...

  • Phenotype

    Loss of visual acuity (implying that vision was better at a certain time point in life). Otherwise t...

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.